1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Clinical Research Network on Antimicrobial Resistance is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) - NIH. NIAID seeks to support a Clinical Research Network on Antimicrobial Resistance (AMR) to design, implement, and manage clinical research addressing key clinical questions in AMR.
This includes evaluating novel diagnostic tests and methods optimizing the use of existing antibiotics, which directly aligns with the development of clinical decision support software for antimicrobial resistance stewardship.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses, for-profit organizations, private institutions of higher education, public and state-controlled institutions of higher education, nonprofits with or without 501(c)(3) IRS status, special district governments, city or township governments, Native American tribal organizations, faith-based or community-based organizations, and regional organizations. Confirm the full requirements on the funder's own website before applying.
The current listing shows up to $12M direct costs/yr; NIAID commits $18M in FY2027 for 1 award (7-yr project). Verify award ceilings, matching requirements, and allowable costs on the funder's own website.
Applications for Clinical Research Network on Antimicrobial Resistance are due November 10, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Clinical Research Network on Antimicrobial Resistance is funded by National Institute of Allergy and Infectious Diseases (NIAID) - NIH. Verify program details on the funder's own website before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleRFA-AI-28-005 recompetes NIAID's Immune Tolerance Network as a single UM1 cooperative agreement: $27M committed in FY2028, budgets capped at $23M a year in direct costs, a mandatory 7-year project period, one application per institution, and a January 29, 2027 deadline. The winner inherits roughly 20 ongoing trials and about 200 sub-agreements.
Read articleNIAID's RFA-AI-28-024 funds preclinical malaria vaccines, from AI-guided design to cGMP lots, through a phased R61/R33. It allows one application per institution, bars foreign subawards, and excludes GLP tox.
Read article